- Home
- KPTI vs DTSQ Comparison
KPTI vs DTSQ Comparison
Compare KPTI & DTSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- DTSQ
- Stock Information
- Founded
- KPTI 2008
- DTSQ 2022
- Country
- KPTI United States
- DTSQ United States
- Employees
- KPTI N/A
- DTSQ N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- DTSQ
- Sector
- KPTI Health Care
- DTSQ
- Exchange
- KPTI Nasdaq
- DTSQ NYSE
- Market Cap
- KPTI 66.7M
- DTSQ 89.8M
- IPO Year
- KPTI 2013
- DTSQ 2024
- Fundamental
- Price
- KPTI $6.94
- DTSQ $10.21
- Analyst Decision
- KPTI Strong Buy
- DTSQ
- Analyst Count
- KPTI 5
- DTSQ 0
- Target Price
- KPTI $61.00
- DTSQ N/A
- AVG Volume (30 Days)
- KPTI 142.7K
- DTSQ 42.9K
- Earning Date
- KPTI 05-07-2025
- DTSQ 01-01-0001
- Dividend Yield
- KPTI N/A
- DTSQ N/A
- EPS Growth
- KPTI N/A
- DTSQ N/A
- EPS
- KPTI N/A
- DTSQ 0.17
- Revenue
- KPTI $145,237,000.00
- DTSQ N/A
- Revenue This Year
- KPTI $4.37
- DTSQ N/A
- Revenue Next Year
- KPTI $19.07
- DTSQ N/A
- P/E Ratio
- KPTI N/A
- DTSQ $61.38
- Revenue Growth
- KPTI N/A
- DTSQ N/A
- 52 Week Low
- KPTI $5.90
- DTSQ $9.96
- 52 Week High
- KPTI $24.75
- DTSQ $10.37
- Technical
- Relative Strength Index (RSI)
- KPTI 39.17
- DTSQ N/A
- Support Level
- KPTI $5.90
- DTSQ N/A
- Resistance Level
- KPTI $8.45
- DTSQ N/A
- Average True Range (ATR)
- KPTI 1.07
- DTSQ 0.00
- MACD
- KPTI -0.01
- DTSQ 0.00
- Stochastic Oscillator
- KPTI 23.21
- DTSQ 0.00
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.